Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
暂无分享,去创建一个
R. Prescott | S. Lewis | J. Satsangi | Fraser Cummings | C. Hawkey | C. Edwards | C. Mowat | S. Travis | N. Kennedy | A. Mckinley | Malcolm A. Smith | D. Gaya | S. Bloom | M. Dunlop | S. Sebastian | J. Lindsay | Tariq Ahmad | J. Thomson | I. Arnott | A. Dhar | C. Nwokolo | S. Lal | S. Campbell | C. Murray | S. Subramanian | S. Lewis | H. Ennis | L. Thomas | G. Naismith | N. Arebi | A. Cahill | John P. Morris | J. Hamlin | T. Creed | M. Yousif | S. Sen | J. Goh | L. Potts | J. Todd | M. Collie | A. Mowat | J. Winter | C. Keerie | J. Morris | S. Lewis
[1] M. Regueiro,et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. , 2016, Gastroenterology.
[2] Steven J Brown,et al. Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.
[3] P. Rutgeerts,et al. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. , 2014, Journal of Crohn's & colitis.
[4] Zhen Wang,et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. , 2015, Gastroenterology.
[5] K. Whelan,et al. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. , 2014, Journal of Crohn's & colitis.
[6] C. Lees,et al. Systematic review: the use of thiopurines or anti‐TNF in post‐operative Crohn's disease maintenance – progress and prospects , 2014, Alimentary pharmacology & therapeutics.
[7] P. Munkholm,et al. Disease Course and Surgery Rates in Inflammatory Bowel Disease: A Population-Based, 7-Year Follow-Up Study in the Era of Immunomodulating Therapy , 2014, The American Journal of Gastroenterology.
[8] H. Ikeuchi,et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3‐year prospective randomized open trial , 2012, Inflammatory bowel diseases.
[9] L. Peyrin-Biroulet,et al. Review article: the natural history of postoperative Crohn's disease recurrence , 2012, Alimentary pharmacology & therapeutics.
[10] 吉田 幸治. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection : a 3-year prospective randomized open trial , 2012 .
[11] C. Lees,et al. Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.
[12] M. Regueiro,et al. Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.
[13] M. Picco. Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection , 2009 .
[14] P. Rutgeerts,et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. , 2008, Gastroenterology.
[15] P. Tekkis,et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies , 2008, International Journal of Colorectal Disease.
[16] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[17] Province,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[18] A. Taschieri,et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. , 2004, Gastroenterology.
[19] R. Thisted,et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.
[20] P. Rutgeerts,et al. Medical management of postoperative recurrence in Crohn's disease. , 2004, Gastroenterology clinics of North America.
[21] A. Weaver,et al. Erythrocyte Mean Corpuscular Volume as a Surrogate Marker for 6-Thioguanine Nucleotide Concentration Monitoring in Patients with Inflammatory Bowel Disease Treated with Azathioprine or 6-Mercaptopurine , 2003, Inflammatory bowel diseases.
[22] P. Rutgeerts,et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.
[23] R. Boulieu,et al. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.
[24] H. Schumacher,et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. , 1996, Annals of surgery.
[25] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.
[26] J Y Mary,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[27] J. Lennard-jones,et al. Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.
[28] S. Kreiner,et al. Alimentary tract andpancreas Prognosis inCrohn's disease -based onresults froma regional patient group fromthecounty ofCopenhagen , 1985 .
[29] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.